microdose vs regular dose glp-1 Microdosing Medications People Are Microdosing Weight-Loss Drugs

When medically appropriate, we prescribe GLP-1s for conditions like cardiac and vascular disease, sleep apnea, kidney disease, type 2 diabetes and stroke risk

Contraindications like a history of pancreatitis or medullary thyroid carcinoma may affect coverage decisions

Interestingly, in our experiments, 10 pmol/L GLP-1 (normal physiological postprandial concentration) suppressed GABA currents (28.11% 12.50% of control) more strongly than 50 nmol/L exendin-4 (69.08% 5.71% of control)

But how do you get it

Next-Generation Profile Successor compound to semaglutide and tirzepatide in mechanism breadth - currently in Phase III trials globally as of 2024

[1] Dehydration from gastrointestinal side effects can increase the risk of acute kidney injury